Your browser doesn't support javascript.
loading
Histopathologic and Clinical Characterization of Brentuximab Vedotin-associated Rash.
Narala, Saisindhu; Saleem, Atif; Brown, Ryanne A; Novoa, Roberto A; Kim, Youn H; Rieger, Kerri E.
Afiliação
  • Narala S; Departments of Pathology.
  • Saleem A; Dermatology, Stanford University School of Medicine, Stanford, CA.
  • Brown RA; Departments of Pathology.
  • Novoa RA; Departments of Pathology.
  • Kim YH; Dermatology, Stanford University School of Medicine, Stanford, CA.
  • Rieger KE; Departments of Pathology.
Am J Surg Pathol ; 48(9): 1131-1137, 2024 Sep 01.
Article em En | MEDLINE | ID: mdl-38907612
ABSTRACT
Rash is one of the commonly observed adverse events with brentuximab vedotin (BV), a CD30-targeted antibody-drug conjugate used to treat cutaneous T-cell lymphoma (CTCL). However, clinical and histopathologic characterization of BV-associated rash (BVAR) is limited. Distinguishing BVAR from a patient's underlying CTCL can be challenging and can lead to treatment interruptions or even premature drug discontinuation. We performed a thorough clinical and histopathologic retrospective characterization of BVAR from a single institution. Utilizing polymerase chain reaction (PCR) and T-cell receptor high-throughput sequencing (TCR-HTS), we were able to isolate skin biopsy specimens from rash clinically suggestive of BVAR that also lacked a dominant TCR clone. A retrospective evaluation was performed of 26 biopsy specimens from 14 patients. Clinical features of BVAR included predominantly morbilliform or maculopapular morphology, delayed onset, and the trend toward moderate to severe classification, often requiring oral steroids. Most histopathologic specimens (25/26) showed spongiotic dermatitis as the primary reaction pattern. Many cases showed subtle findings to support a background interface or lichenoid eruption. Langerhans cell microabscesses were seen in one-fourth of specimens, and eosinophils were present in over one-half of the specimens. There were focal features mimicking CTCL, but these were not prominent. In 17 specimens with immunohistochemistry, the CD4CD8 ratio in intraepidermal lymphocytes was relatively normal (1-61) in 65% (11/17) and 11 in 35% (6/17), demonstrating a trend toward increased CD8-positive cells compared with baseline CTCL. We have identified features that can help distinguish BVAR from a patient's CTCL, which can, in turn, help guide appropriate clinical management.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Cutâneo de Células T / Toxidermias / Exantema / Brentuximab Vedotin Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Surg Pathol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Cutâneo de Células T / Toxidermias / Exantema / Brentuximab Vedotin Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Surg Pathol Ano de publicação: 2024 Tipo de documento: Article